ArticleNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2022
Assessment of IQOS Marketing Strategies at Points-of-Sale in Israel at a Time of Regulatory Transition.
Article in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- IQOS news media coverage in Israel: a comparison across three subpopulations.Tobacco control · 2025Article
- Low compliance and proliferation of IQOS purchase cues at points-of-sale: a comparative study before and after Israel's display ban.Tobacco control · 2025Article
- Industry Strategies for Attracting Youth to Cigarettes, E-cigarettes, and HTPs: Retailer Density and Marketing at Points-of-Sale in Vietnam and the Philippines.Asian Pacific journal of cancer prevention : APJCP · 2025Observational
- IQOS point-of-sale marketing: a comparison between Arab and Jewish neighborhoods in Israel.Israel journal of health policy research · 2024Article
- Heated tobacco product marketing: a mixed-methods study examining exposure and perceptions among US and Israeli adults.Health education research · 2024Article
- IQOS and cigarette advertising across regulatory periods and population groups in Israel: a longitudinal analysis.Tobacco control · 2024Article
- PMI's IQOS and cigarette ads in Israeli media: a content analysis across regulatory periods and target population subgroups.Tobacco control · 2024Article
- IQOS point-of-sale marketing: a comparison between Arab and Jewish neighborhoods in Israel.Research square · 2024Article
- Nicotine pouch marketing strategies in the USA: an analysis of Zyn, On! and Velo.Tobacco control · 2024Article
- Romanian young adult perceptions on using heated tobacco products following exposure to direct marketing methods.NPJ primary care respiratory medicine · 2023Article
- IQOS Use and Interest by Sociodemographic and Tobacco Behavior Characteristics among Adults in the US and Israel.International journal of environmental research and public health · 2023Article
- Proximity of IQOS and JUUL points of sale to schools in Israel: a geospatial analysis.Tobacco control · 2022Article
- IQOS Marketing in the US: The Need to Study the Impact of FDA Modified Exposure Authorization, Marketing Distribution Channels, and Potential Targeting of Consumers.International journal of environmental research and public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionIQOS, a tobacco heating system, and accompanying tobacco sticks (HEETS) entered the Israeli market in 2016, prior to rapid regulatory change. This study assessed IQOS marketing strategies and regulatory compliance at IQOS and/or HEETS point-of-sale (POS) in Israel in December 17, 2019 to January 7, 2020, after the ban on advertisement went into effect in March 8, 2019. AIMS AND
methodsResearch staff audited 80 randomly selected IQOS and/or HEETS POS in four cities using a structured form to assess store types, product placement, price, promotional strategies, and regulatory compliance. POS data were linked to neighborhood characteristics, including socioeconomic status, ethnicity, and proximity (under 300 m) to schools.
resultsAlmost half of the stores (48.7%) were convenience stores. HEETS were visible to the customers in 46.1% of POS, 35% carried at least four HEETS colors, 20.0% had IQOS and/or HEETS special displays, and 13.8% displayed HEETS near youth-oriented merchandise. Mean HEETS pack price was US $8.7 (range: US $7.5-11.3), 27% more than the least expensive cigarette pack, and 39% less than the most expensive cigarette. HEETS promotions were uncommon. Compliance with the newly introduced advertisement ban was fairly high for HEETS (94.8%). Only one POS was located in a low-socioeconomic status area; 68.7% were near a school.
conclusionsThe relatively limited IQOS and/or HEETS marketing at POS suggests that, with regulatory changes, online or other forms of marketing might be prioritized. IQOS may be promoted to higher socioeconomic status populations, as indicated by pricing and POS neighborhood characteristics. Access near schools and placement near youth-oriented merchandise are potential concerns necessitating further research. IMPLICATIONS: Globally, the POS is considered the least regulated channel for advertising and marketing of tobacco products. Assessing IQOS marketing strategies at the POS provides valuable findings that can inform regulatory efforts in Israel and other countries as well. Limited IQOS and/or HEETS marketing at POS suggests that primary marketing strategies may shift to online or other channels as regulatory contexts become more progressive and/or restrictive. Ongoing surveillance of IQOS via online marketing and POSs, specifically with regard to product placement and proximity to schools, is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.